- Warhammer maker Games Workshop enters London's top stocks index
- Iran Nobel winner released for three weeks, 'unconditional' freedom urged
- Red Cross marks record numbers of humanitarians killed in 2024
- Johnson's Grand Slam 'no threat', says World Athletics boss Coe
- Qatar's emir and UK's Starmer talk trade as state visit ends
- Cuba suffers third nationwide blackout in two months
- Russia, Ukraine to send top diplomats to OSCE summit in Malta
- Spanish royals to attend memorial service for flood victims
- LPGA, USGA new policy requires female at birth or pre-puberty change
- Stick to current climate change laws, US tells top UN court
- British Museum chief says Marbles deal with Greece 'some distance' away
- Pope Francis receives electric popemobile from Mercedes
- Gaza civil defence: thousands flee Israeli strikes, evacuation calls
- Trump names billionaire private astronaut as next NASA chief
- Pidcock to leave INEOS Grenadiers at end of season
- Seoul stocks weaken, Paris advances despite political turmoil
- South America summit hopes to seal 'historic' trade deal with EU
- DAZN awarded global TV rights for Club World Cup
- Top executive shot dead outside New York hotel
- Vaping while still smoking unlikely to help quitters: study
- British Museum chief says Parthenon Marbles deal with Greece 'some distance' away
- 'Creating connections': Arab, African filmmakers gather at Morocco workshops
- Iran frees Nobel winner for three weeks, sparking calls for 'permanent' release
- Brazil's Minas cheese gets added to UNESCO list
- Top US executive shot dead in New York City: media
- Trump's nominee to run Pentagon hangs by a thread
- GM announces more than $5 bn hit to earnings in China venture
- World chess champ Ding, teen challenger tied past halfway mark
- Georgia police raid opposition offices as PM vows to curb protests
- S. Korea opposition begins push to impeach president
- Syrian army fights rebel offensive with counterattack
- France court upholds Polanski acquittal in defamation case
- UK bans daytime TV ads for cereals, muffins and burgers
- Palace's Guehi to face no formal action over 'Jesus' message on rainbow armband
- UK faces trade balancing act with Trump, EU
- Iran releases Nobel Peace laureate Mohammadi on medical leave: lawyer
- UNESCO grants heritage status to Aleppo soap as Syria war flares
- Ghana's illegal mining boom seeps into presidential election
- Inconsistent Spurs 'progressing in all aspects': Postecoglou
- France's Orano says Niger junta controls uranium firm
- Seoul stocks weaken, Paris edges up tracking political turmoil
- China reports warmest autumn since records began
- French marine park to close over law banning killer whale shows
- Thousands march demanding S. Korea president resign over martial law debacle
- Taiwan romance novelist Chiung Yao dies at 86
- In Angola, Biden promises to invest differently to China
- Syrian army launches counteroffensive against rebels
- Evenepoel says 'long journey' ahead after postal van collision
- South Korea's day of rage as Yoon's martial law founders
- UK police question killer nurse Letby over further baby deaths
Ketamine pill treats depression without psychedelic effects: study
A new pill that slowly releases ketamine could treat people with severe depression without giving them the psychedelic side effects of the often-misused drug, early trial results suggested on Monday.
First developed in the 1960s as an anaesthetic, ketamine's hallucinogenic and dissociative effects led to it becoming a party drug dubbed "Special K".
However, mounting research has demonstrated that ketamine is effective for the roughly quarter of people suffering from depression who see little benefit from common anti-depressant drugs.
In many countries, ketamine has been prescribed for depression for years.
US billionaire Elon Musk told CNN in March that he regularly uses a small amount of prescribed ketamine because it is "helpful for getting one out of the negative frame of mind".
The drug has long been administered intravenously in clinics, but more recently a nasal spray using a derivative called esketamine has increased in popularity.
Both can cause patients to have side effects such as dissociation, high blood pressure and an elevated heart rate.
There are also fears that medical use of the drug could slide into abuse.
The pill described in the journal Nature Medicine on Monday takes more than 10 hours to break down in the liver, lead study author Paul Glue told AFP.
"The really interesting feedback from patients is the lack of side effects -- no euphoria, no dissociation," said the researcher at New Zealand's University of Otago.
"I don't think these tablets would appeal to people who are abusing ketamine."
- Electro-shock alternative -
The phase 2 trial involved more than 270 people with depression who had previously tried an average of four different anti-depressant drugs.
More than half taking the ketamine pill went into remission for their depression, while 70 percent of the placebo group relapsed after 13 weeks, the study said.
Julaine Allan, an expert on mental health and addiction at Australia's Charles Sturt University who was not involved in the study, praised the trial while emphasising that more research is needed.
Ketamine does not work for everyone, and the "positive effects may wear off over time," she told AFP.
Michel Hoffmann, a psychiatrist at Geneva University Hospitals, said there is "real enthusiasm" in the medical community for ketamine's potential for treating depression.
"For patients who don't respond to conventional drugs, ketamine offers a way to avoid electro-shock therapy," he told AFP.
This last-resort treatment, which involves sending electric currents through the brain, has been proven to be effective.
But it can cause memory loss -- and some patients fear the procedure after seeing depictions of it in films such as "One Flew Over the Cuckoo's Nest".
- Fears of 'opioid style crisis' -
Some psychiatrists remain hesitant to prescribe ketamine for depression, fearing their patients could end up misusing the drug.
Last year, "Friends" actor Matthew Perry became the latest high-profile death from a ketamine overdose.
US police are investigating how Perry obtained the doses that caused his death -- he had reportedly not had a supervised infusion session for several days.
One potential benefit of quick-acting ketamine seen in previous research is that it could help patients considering suicide.
But there is "the plausible concern that the widespread use of ketamine might trigger a new opioid style crisis," Oxford researcher Riccardo De Giorgi said in a 2022 BMJ editorial.
By ridding ketamine of the side effects sought by some partygoers, the slow-release pill could alleviate some of these concerns.
There were still some side effects from the pill, the most common being headaches, dizziness and anxiety.
More research including phase 3 trials is needed before the drug can be reviewed by national medicine agencies, meaning it will be at least two or three years before patients could potentially access the pills, Glue said.
F.Pavlenko--BTB